Piscitelli, Joseph http://orcid.org/0009-0009-1174-966X
Reddy, Micaela B.
Wollenberg, Lance
Del Frari, Laurence
Gong, Jason
Wood, Linda
Zhang, Yizhong
Matschke, Kyle
Williams, Jason H.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration
https://doi.org/10.1007/s40262-024-01352-9
Funding for this research was provided by:
Pfizer
Article History
Accepted: 30 January 2024
First Online: 29 February 2024
Declarations
:
: This work was sponsored by Pfizer.
: J.P., M.B.R., L.W., J.G., L.W., Y.Z., K.M., and J.H.W. are employees of Pfizer and hold Pfizer stock. L.D.F. is an employee of Pierre Fabre Medicament.
: Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See for more information.
: These studies were conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines. In addition, all local regulatory requirements were followed, particularly those affording greater protection to the safety of trial participants. An institutional review board approved the protocols, and all participants gave written informed consent. This trial was registered on ClinicalTrials.gov: NCT03864042.
: All participants provided written informed consent before undergoing any study procedures.
: JP, MBR, LW, LDF, JG, LW, YZ, KM, and JHW designed and performed the research, analyzed the data, and wrote the manuscript.